ZNF740 and acute myeloid leukemia: Interestingly, we found that ZNF740 expression levels in AML-M4 and AML-M5 subtypes were significantly lower compared to the other FAB subtypes (Fig. 1F), which was consistent with our findings that ZNF740 loss results in venetoclax resistance.